Drug interactions
Budesonide + Metformin-repaglinide
Severity: Minor
Budesonide and Metformin-repaglinide: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Budesonide is a CYP3A4 substrate with a glucocorticoid effect, and systemic exposure can raise blood glucose. Any effect on repaglinide through enzyme induction is minor and unlikely to matter with inhaled or low-dose use. The main concern is reduced glycemic control with systemic exposure.
What this interaction means in plain words
Budesonide and Metformin-repaglinide have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Budesonide belongs to Respiratory; Metformin-repaglinide belongs to Endocrine.
Why it happens
Glucocorticoid-mediated hyperglycemia; weak possible CYP3A4 induction affecting repaglinide.
What to do
Monitor blood glucose when budesonide is given orally or in higher doses, and adjust antidiabetic doses if needed.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Budesonide and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Budesonide
Frequently asked questions
Can I take Budesonide with Metformin-repaglinide?
MediHelp rates the interaction as minor. Budesonide and Metformin-repaglinide have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Budesonide is a CYP3A4 substrate with a glucocorticoid effect, and systemic exposure can raise blood glucose. Any effect on repaglinide through enzyme induction is minor and unlikely to matter with inhaled or low-dose use. The main concern is reduced glycemic control with systemic exposure.
How serious is the interaction between Budesonide and Metformin-repaglinide?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose when budesonide is given orally or in higher doses, and adjust antidiabetic doses if needed.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
